|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-6-8
|
|
pubmed:abstractText |
Over 700 patients with HIV-associated wasting while receiving HAART were randomly assigned to double-blind treatment for 12 weeks with recombinant human growth hormone (rhGH) daily or on alternate days, or to placebo. Maximum exercise intensity increased by a median of 2.35kJ in the alternate-days group and 2.60 kJ in the daily group but decreased by 0.25kJ in the placebo group. The median difference between the daily and placebo groups was 2.85 kJ (P < .0001). These improvements suggest that rhGH treatment may enable patients with wasting to perform activities of daily living that would be exhausting without rhGH treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
X
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1053-0894
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
301-3, 306-8, 310, 314
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15962453-Adult,
pubmed-meshheading:15962453-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15962453-Body Composition,
pubmed-meshheading:15962453-Dose-Response Relationship, Drug,
pubmed-meshheading:15962453-Double-Blind Method,
pubmed-meshheading:15962453-Drug Administration Schedule,
pubmed-meshheading:15962453-Drug Therapy, Combination,
pubmed-meshheading:15962453-Exercise Tolerance,
pubmed-meshheading:15962453-Female,
pubmed-meshheading:15962453-Follow-Up Studies,
pubmed-meshheading:15962453-HIV Wasting Syndrome,
pubmed-meshheading:15962453-Human Growth Hormone,
pubmed-meshheading:15962453-Humans,
pubmed-meshheading:15962453-Male,
pubmed-meshheading:15962453-Middle Aged,
pubmed-meshheading:15962453-Probability,
pubmed-meshheading:15962453-Recombinant Proteins,
pubmed-meshheading:15962453-Reference Values,
pubmed-meshheading:15962453-Risk Assessment,
pubmed-meshheading:15962453-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.
|
|
pubmed:affiliation |
Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
